China News Service, July 1, according to Japanese media reports, on June 30 local time, a biological start-up company in Ibaraki City, Osaka Prefecture, Japan announced that it has launched a clinical trial to confirm the safety and effectiveness of injecting a new crown vaccine into humans. Sex. This is the first clinical trial of a new crown vaccine in Japan. The company hopes that if it can show safety and effectiveness, it hopes to be approved for sale in 2021.

On June 6, local time, a shopping mall in Tokyo, Japan reminded customers to pay attention to the interval when taking the elevator. China News Service reporter Lu Shaowei

  According to the Japan Broadcasting Association (NHK), the company is called "AnGes" and is a biological startup established by researchers at Osaka University. The company said it plans to administer a "DNA vaccine" to 30 healthy adults at the affiliated hospital of the Osaka City University School of Medicine.

  According to reports, this vaccine is not made using the virus itself, but uses the genetic gene of the "spike protein" that is located on the surface of the virus and functions when infecting cells. After injecting the gene-introduced substance into the human body, "spike protein" will appear in the body, and then, under the action of the immune mechanism, antibodies will be produced to prevent the human body from being infected.

  Vaccine injections were performed in 2 sessions, with a 2-week interval between them. Thirty vaccinators were divided into two groups, 15 people in each group. The injection volume of the two groups was different to compare the safety and antibody formation of different doses.

  It is reported that many countries in the world have embarked on clinical trials of the new crown vaccine, but this is the first time in Japan. The company's relevant person said that it intends to enter the next phase of clinical trials in autumn 2020.

  According to Kyodo News of Japan, "AnGes" said that if it can show safety and effectiveness, then it is hoped that it will obtain national production and sales approval from spring to autumn from 2021.